TRIENTINE Drug Patent Profile
✉ Email this page to a colleague
When do Trientine patents expire, and when can generic versions of Trientine launch?
Trientine is a drug marketed by Accord Hlthcare, Amneal, Chartwell Rx, Dr Reddys, Eci Pharms Llc, Hetero Labs Ltd Iii, Lupin, MSN, Navinta Llc, Ph Health, Rising, Watson Labs Teva, and Zydus Pharms. and is included in thirteen NDAs.
The generic ingredient in TRIENTINE is trientine hydrochloride. There are ten drug master file entries for this compound. Seven suppliers are listed for this compound. Additional details are available on the trientine hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Trientine
A generic version of TRIENTINE was approved as trientine hydrochloride by WATSON LABS TEVA on February 7th, 2018.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for TRIENTINE?
- What are the global sales for TRIENTINE?
- What is Average Wholesale Price for TRIENTINE?
Summary for TRIENTINE
| US Patents: | 0 |
| Applicants: | 13 |
| NDAs: | 13 |
| Drug Prices: | Drug price information for TRIENTINE |
| DailyMed Link: | TRIENTINE at DailyMed |
US Patents and Regulatory Information for TRIENTINE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Accord Hlthcare | TRIENTINE HYDROCHLORIDE | trientine hydrochloride | CAPSULE;ORAL | 212929-001 | Aug 30, 2021 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Lupin | TRIENTINE HYDROCHLORIDE | trientine hydrochloride | CAPSULE;ORAL | 211637-001 | May 21, 2020 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Dr Reddys | TRIENTINE HYDROCHLORIDE | trientine hydrochloride | CAPSULE;ORAL | 211076-001 | Jul 3, 2019 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Rising | TRIENTINE HYDROCHLORIDE | trientine hydrochloride | CAPSULE;ORAL | 212238-002 | Sep 22, 2023 | RX | No | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
